Drug Interactions between fenfluramine and hydroxychloroquine
This report displays the potential drug interactions for the following 2 drugs:
- fenfluramine
- hydroxychloroquine
Interactions between your drugs
fenfluramine hydroxychloroquine
Applies to: fenfluramine and hydroxychloroquine
MONITOR: Coadministration with inhibitors of CYP450 1A2 or 2D6 may increase the plasma concentrations of fenfluramine. Over 75% of fenfluramine is metabolized to norfenfluramine prior to elimination, primarily by CYP450 1A2, 2B6 and 2D6, but also to a minor extent by CYP450 2C9, 2C19 and 3A4/5. When a single 0.35 mg/kg dose of fenfluramine oral solution was coadministered with 50 mg once daily fluvoxamine (a potent CYP450 1A2 inhibitor) at steady state in healthy volunteers, fenfluramine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 22% and 102%, respectively, while the Cmax and AUC of norfenfluramine decreased by 44% and 22%, respectively. Coadministration with 30 mg once daily paroxetine (a potent CYP450 2D6 inhibitor) at steady state in healthy volunteers increased the Cmax and AUC of fenfluramine by 13% and 81%, respectively, and decreased Cmax and AUC of norfenfluramine by 29% and 13%, respectively. Coadministration with repeated doses of cannabidiol (a weak CYP450 1A2 inhibitor with the potential to also inhibit CYP450 2B6, 2C8, 2C9, and 2C19 at clinically relevant concentrations) increased the Cmax and AUC of fenfluramine by 10% and 59%, respectively, and decreased Cmax and AUC of norfenfluramine by 33% and 22%, respectively. Elevated plasma levels of fenfluramine may increase the risk of serious adverse effects such as valvular heart disease, pulmonary arterial hypertension, blood pressure increases, and serotonin syndrome.
MANAGEMENT: Caution is advised when fenfluramine is used with CYP450 1A2 or 2D6 inhibitors. Patients should be monitored for increased adverse effects, and the dosage of fenfluramine adjusted as necessary.
References (2)
- (2020) "Product Information. Fintepla (fenfluramine)." Zogenix, Inc
- (2023) "Product Information. Fintepla (fenfluramine)." UCB Pharma Ltd, SUPPL-13
Drug and food interactions
fenfluramine food
Applies to: fenfluramine
GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.
MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (3)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
- (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals
hydroxychloroquine food
Applies to: hydroxychloroquine
GENERALLY AVOID: Theoretically, grapefruit and grapefruit juice may increase the plasma concentrations of hydroxychloroquine or chloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruit. Following coadministration with cimetidine, a weak to moderate CYP450 3A4 inhibitor, a 2-fold increase in chloroquine exposure occurred. Since chloroquine and hydroxychloroquine have similar structures and metabolic elimination pathways, a similar interaction may be observed with hydroxychloroquine. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
ADJUST DOSING INTERVAL: Administration with food or milk may reduce the incidence of hydroxychloroquine-related gastrointestinal adverse effects.
MANAGEMENT: Although clinical data are lacking, it may be advisable to avoid the consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract during hydroxychloroquine or chloroquine therapy. Hydroxychloroquine should be administered with food or milk to reduce the occurrence of gastrointestinal upset.
References (5)
- (2024) "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Dr. Reddy's Laboratories Inc
- (2023) "Product Information. Plaquenil (hydroxychloroquine)." Sanofi-Aventis Canada Inc
- (2024) "Product Information. Quinoric (hydroxychloroquine)." Bristol Laboratories Ltd
- (2024) "Product Information. Hydroxychloroquine (GH) (hydroxychloroquine)." Generic Health Pty Ltd
- (2023) "Product Information. HIDROXICLOROQUINA RATIOPHARM (hidroxicloroquina)." RATIOPHARM ESPANA S.A.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.